Cover Image
市場調查報告書

Domainex Ltd.- 產品平台檢討

Domainex Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293906
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Domainex Ltd.- 產品平台檢討 Domainex Ltd. - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 29 Pages
簡介

Domainex Ltd.是總公司設立於英國的生物科技企業,提供您藥物研發的技術及服務。主要提供標的表現,結構生物學,虛擬篩檢,醫藥品化學,電腦化學,化驗開發等藥物遞輸服務。利用功能域結合、片段型篩檢等技術平台。

本報告提供Domainex Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Domainex Ltd.的基本資料

  • Domainex Ltd.概要
  • 主要資訊
  • 企業資料

Domainex Ltd.:R&D概要

  • 主要的治療範圍

Domainex Ltd.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Domainex Ltd.:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Domainex Ltd.:藥物簡介

  • Small Molecule to Inhibit FLIP Protein for NSCLC
  • Small Molecules to Inhibit TBK1/ IKKe for Cancer and Inflammatory Diseases
  • Small Molecule to Inhibit G9a For Cancer
  • Small Molecule to Inhibit KMT Target 4 for Cancer
  • Small Molecule to Inhibit KMT Target 5 For Cancer
  • Small Molecule to Inhibit SMYD3 Protein for Cancer
  • Small Molecules to Inhibit EZH2 for Oncology

Domainex Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Domainex Ltd.:最近的開發平台資訊

Domainex Ltd.:暫停開發中的計劃

Domainex Ltd.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07120CDB

Summary

Global Markets Direct's, 'Domainex Ltd. - Product Pipeline Review - 2015', provides an overview of the Domainex Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Domainex Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Domainex Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Domainex Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Domainex Ltd.'s pipeline products

Reasons to buy

  • Evaluate Domainex Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Domainex Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Domainex Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Domainex Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Domainex Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Domainex Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Domainex Ltd. Snapshot
    • Domainex Ltd. Overview
    • Key Information
    • Key Facts
  • Domainex Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Domainex Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Domainex Ltd. - Pipeline Products Glance
    • Domainex Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Domainex Ltd. - Drug Profiles
    • Small Molecule to Inhibit FLIP Protein for NSCLC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit TBK1/ IKKe for Cancer and Inflammatory Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit G9a For Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit KMT Target 4 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit KMT Target 5 For Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit SMYD3 Protein for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit EZH2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Domainex Ltd. - Pipeline Analysis
    • Domainex Ltd. - Pipeline Products by Target
    • Domainex Ltd. - Pipeline Products by Route of Administration
    • Domainex Ltd. - Pipeline Products by Molecule Type
    • Domainex Ltd. - Pipeline Products by Mechanism of Action
  • Domainex Ltd. - Recent Pipeline Updates
  • Domainex Ltd. - Dormant Projects
  • Domainex Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Domainex Ltd., Key Information
  • Domainex Ltd., Key Facts
  • Domainex Ltd. - Pipeline by Indication, 2015
  • Domainex Ltd. - Pipeline by Stage of Development, 2015
  • Domainex Ltd. - Monotherapy Products in Pipeline, 2015
  • Domainex Ltd. - Partnered Products in Pipeline, 2015
  • Domainex Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Domainex Ltd. - Preclinical, 2015
  • Domainex Ltd. - Discovery, 2015
  • Domainex Ltd. - Pipeline by Target, 2015
  • Domainex Ltd. - Pipeline by Route of Administration, 2015
  • Domainex Ltd. - Pipeline by Molecule Type, 2015
  • Domainex Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Domainex Ltd. - Recent Pipeline Updates, 2015
  • Domainex Ltd. - Dormant Developmental Projects,2015

List of Figures

  • Domainex Ltd. - Pipeline by Top 10 Indication, 2015
  • Domainex Ltd. - Pipeline by Stage of Development, 2015
  • Domainex Ltd. - Monotherapy Products in Pipeline, 2015
  • Domainex Ltd. - Pipeline by Top 10 Target, 2015
  • Domainex Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Domainex Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top